
Jia-hai Lee
Examiner (ID: 893, Phone: (571)270-1691 , Office: P/1676 )
| Most Active Art Unit | 1658 |
| Art Unit(s) | 1676, 1658 |
| Total Applications | 561 |
| Issued Applications | 242 |
| Pending Applications | 104 |
| Abandoned Applications | 235 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 16437095
[patent_doc_number] => 20200354421
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-11-12
[patent_title] => NEUREGULIN-4 COMPOUNDS AND METHODS OF USE
[patent_app_type] => utility
[patent_app_number] => 16/835787
[patent_app_country] => US
[patent_app_date] => 2020-03-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12937
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -29
[patent_words_short_claim] => 13
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16835787
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/835787 | Neuregulin-4 compounds and methods of use | Mar 30, 2020 | Issued |
Array
(
[id] => 16253514
[patent_doc_number] => 20200262888
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-08-20
[patent_title] => LONG-ACTING CONJUGATES OF GLP-2 DERIVATIVES
[patent_app_type] => utility
[patent_app_number] => 16/832634
[patent_app_country] => US
[patent_app_date] => 2020-03-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14784
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -21
[patent_words_short_claim] => 80
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16832634
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/832634 | Long-acting conjugates of GLP-2 derivatives | Mar 26, 2020 | Issued |
Array
(
[id] => 17790529
[patent_doc_number] => 20220249620
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-08-11
[patent_title] => COMPOSITION COMPRISING RECOMBINANT PARATHYROID HORMONE FOR HEALING AFTER ROTATOR CUFF REPAIR
[patent_app_type] => utility
[patent_app_number] => 17/599744
[patent_app_country] => US
[patent_app_date] => 2020-03-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7256
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -7
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17599744
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/599744 | COMPOSITION COMPRISING RECOMBINANT PARATHYROID HORMONE FOR HEALING AFTER ROTATOR CUFF REPAIR | Mar 26, 2020 | Pending |
Array
(
[id] => 16204866
[patent_doc_number] => 20200237856
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-07-30
[patent_title] => METHOD OF TREATING PATIENTS WITH HEPATORENAL SYNDROME TYPE 1
[patent_app_type] => utility
[patent_app_number] => 16/828681
[patent_app_country] => US
[patent_app_date] => 2020-03-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12566
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -33
[patent_words_short_claim] => 96
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16828681
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/828681 | METHOD OF TREATING PATIENTS WITH HEPATORENAL SYNDROME TYPE 1 | Mar 23, 2020 | Abandoned |
Array
(
[id] => 16221302
[patent_doc_number] => 20200246418
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-08-06
[patent_title] => METHOD OF TREATING PATIENTS WITH HEPATORENAL SYNDROME TYPE 1
[patent_app_type] => utility
[patent_app_number] => 16/828674
[patent_app_country] => US
[patent_app_date] => 2020-03-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9557
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 117
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16828674
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/828674 | METHOD OF TREATING PATIENTS WITH HEPATORENAL SYNDROME TYPE 1 | Mar 23, 2020 | Abandoned |
Array
(
[id] => 16310915
[patent_doc_number] => 20200289653
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-09-17
[patent_title] => IMPROVED PEPTIDE PHARMACEUTICALS FOR INSULIN RESISTANCE
[patent_app_type] => utility
[patent_app_number] => 16/826208
[patent_app_country] => US
[patent_app_date] => 2020-03-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 29773
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16826208
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/826208 | IMPROVED PEPTIDE PHARMACEUTICALS FOR INSULIN RESISTANCE | Mar 20, 2020 | Pending |
Array
(
[id] => 16310915
[patent_doc_number] => 20200289653
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-09-17
[patent_title] => IMPROVED PEPTIDE PHARMACEUTICALS FOR INSULIN RESISTANCE
[patent_app_type] => utility
[patent_app_number] => 16/826208
[patent_app_country] => US
[patent_app_date] => 2020-03-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 29773
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16826208
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/826208 | IMPROVED PEPTIDE PHARMACEUTICALS FOR INSULIN RESISTANCE | Mar 20, 2020 | Pending |
Array
(
[id] => 18182000
[patent_doc_number] => 20230042729
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-02-09
[patent_title] => PEPTIDE CONSTRUCTS AND COMPOSITIONS
[patent_app_type] => utility
[patent_app_number] => 17/438762
[patent_app_country] => US
[patent_app_date] => 2020-03-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 22462
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17438762
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/438762 | PEPTIDE CONSTRUCTS AND COMPOSITIONS | Mar 12, 2020 | Pending |
Array
(
[id] => 16310882
[patent_doc_number] => 20200289620
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-09-17
[patent_title] => THERAPEUTIC AGENT PREPARATIONS AND METHODS FOR DRUG DELIVERY INTO A LUMEN OF THE INTESTINAL TRACT USING A SWALLOWABLE DRUG DELIVERY DEVICE
[patent_app_type] => utility
[patent_app_number] => 16/817490
[patent_app_country] => US
[patent_app_date] => 2020-03-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 31880
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 73
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16817490
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/817490 | THERAPEUTIC AGENT PREPARATIONS AND METHODS FOR DRUG DELIVERY INTO A LUMEN OF THE INTESTINAL TRACT USING A SWALLOWABLE DRUG DELIVERY DEVICE | Mar 11, 2020 | Abandoned |
Array
(
[id] => 16791700
[patent_doc_number] => 20210121517
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-04-29
[patent_title] => STABLE PARENTERAL DOSAGE FORM OF CETRORELIX ACETATE
[patent_app_type] => utility
[patent_app_number] => 16/814447
[patent_app_country] => US
[patent_app_date] => 2020-03-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7128
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -21
[patent_words_short_claim] => 86
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16814447
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/814447 | STABLE PARENTERAL DOSAGE FORM OF CETRORELIX ACETATE | Mar 9, 2020 | Pending |
Array
(
[id] => 16312326
[patent_doc_number] => 20200291064
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-09-17
[patent_title] => PURIFICATION OF POLYPEPTIDES USING DUAL STAGE TANGENTIAL-FLOW ULTRAFILTRATION
[patent_app_type] => utility
[patent_app_number] => 16/798141
[patent_app_country] => US
[patent_app_date] => 2020-02-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 33970
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16798141
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/798141 | PURIFICATION OF POLYPEPTIDES USING DUAL STAGE TANGENTIAL-FLOW ULTRAFILTRATION | Feb 20, 2020 | Abandoned |
Array
(
[id] => 17578796
[patent_doc_number] => 20220135651
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-05-05
[patent_title] => A MEMBRANE-BOUND FIT-1 DECOY AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/430037
[patent_app_country] => US
[patent_app_date] => 2020-02-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 18820
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 30
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17430037
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/430037 | A MEMBRANE-BOUND FIT-1 DECOY AND USES THEREOF | Feb 16, 2020 | Abandoned |
Array
(
[id] => 18434402
[patent_doc_number] => 20230181696
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-06-15
[patent_title] => POLYPEPTIDE DRUG FOR PREVENTING AND/OR TREATING NEUROBLASTOMA AND USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/799552
[patent_app_country] => US
[patent_app_date] => 2020-02-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 4738
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -1
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17799552
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/799552 | POLYPEPTIDE DRUG FOR PREVENTING AND/OR TREATING NEUROBLASTOMA AND USE THEREOF | Feb 16, 2020 | Abandoned |
Array
(
[id] => 16252168
[patent_doc_number] => 20200261542
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-08-20
[patent_title] => FGF21 COMPOUND / GLP-1R AGONIST COMBINATIONS WITH OPTIMIZED ACTIVITY RATIO
[patent_app_type] => utility
[patent_app_number] => 16/751581
[patent_app_country] => US
[patent_app_date] => 2020-01-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16742
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16751581
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/751581 | FGF21 COMPOUND / GLP-1R AGONIST COMBINATIONS WITH OPTIMIZED ACTIVITY RATIO | Jan 23, 2020 | Abandoned |
Array
(
[id] => 16153927
[patent_doc_number] => 20200215196
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-07-09
[patent_title] => MINIMALLY TOXIC PRODRUGS
[patent_app_type] => utility
[patent_app_number] => 16/751668
[patent_app_country] => US
[patent_app_date] => 2020-01-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 26535
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -1
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16751668
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/751668 | MINIMALLY TOXIC PRODRUGS | Jan 23, 2020 | Abandoned |
Array
(
[id] => 15800125
[patent_doc_number] => 20200123205
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-04-23
[patent_title] => Inhibition Of TCR Signaling With Peptide Variants
[patent_app_type] => utility
[patent_app_number] => 16/719103
[patent_app_country] => US
[patent_app_date] => 2019-12-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 29414
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16719103
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/719103 | Inhibition Of TCR Signaling With Peptide Variants | Dec 17, 2019 | Pending |
Array
(
[id] => 15800125
[patent_doc_number] => 20200123205
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-04-23
[patent_title] => Inhibition Of TCR Signaling With Peptide Variants
[patent_app_type] => utility
[patent_app_number] => 16/719103
[patent_app_country] => US
[patent_app_date] => 2019-12-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 29414
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16719103
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/719103 | Inhibition Of TCR Signaling With Peptide Variants | Dec 17, 2019 | Pending |
Array
(
[id] => 15800125
[patent_doc_number] => 20200123205
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-04-23
[patent_title] => Inhibition Of TCR Signaling With Peptide Variants
[patent_app_type] => utility
[patent_app_number] => 16/719103
[patent_app_country] => US
[patent_app_date] => 2019-12-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 29414
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16719103
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/719103 | Inhibition Of TCR Signaling With Peptide Variants | Dec 17, 2019 | Pending |
Array
(
[id] => 15800125
[patent_doc_number] => 20200123205
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-04-23
[patent_title] => Inhibition Of TCR Signaling With Peptide Variants
[patent_app_type] => utility
[patent_app_number] => 16/719103
[patent_app_country] => US
[patent_app_date] => 2019-12-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 29414
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16719103
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/719103 | Inhibition Of TCR Signaling With Peptide Variants | Dec 17, 2019 | Pending |
Array
(
[id] => 17843794
[patent_doc_number] => 11433137
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-09-06
[patent_title] => Compounds for treating cancer
[patent_app_type] => utility
[patent_app_number] => 16/714938
[patent_app_country] => US
[patent_app_date] => 2019-12-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 17
[patent_figures_cnt] => 14
[patent_no_of_words] => 38984
[patent_no_of_claims] => 28
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 130
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16714938
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/714938 | Compounds for treating cancer | Dec 15, 2019 | Issued |